Group 1 - Patient Opportunity Equity Strategy achieved a return of 5.99% net of fees in Q4 2025, outperforming the S&P 500 Index which returned 2.65% [1] - The overall market experienced a strong year with a return of 17.9%, marking the seventh-best three-year period in market history [1] - The strategy outperformed the S&P 500 for the third consecutive year with a total return of 26.1% [1] Group 2 - Precigen, Inc. (NASDAQ:PGEN) was highlighted as a leading contributor to the strategy, focusing on gene and cell therapies in immuno-oncology, autoimmune disorders, and infectious diseases [2] - As of March 04, 2026, Precigen, Inc. had a stock price of $3.55 per share, with a one-month return of -16.27% and a 52-week gain of 89.84% [2] - Precigen, Inc. has a market capitalization of $1.256 billion [2] Group 3 - Precigen, Inc. received early approval for Papziemos, the first-in-class "off-the-shelf" immunotherapy for recurrent respiratory papillomatosis (RRP), which is significant for patients with no other treatment options [3] - The company is moving quickly to launch Papziemos, which may lead to self-funding and advancement of other pipeline assets [3] - Dr. Helen Sabzevari, leading the company, has a strong background in immunotherapy and is expected to drive progress in other pipeline assets currently in development [3]